Intramuscular Anti‐D treatment for immune thrombocytopenia: A single centre experience

Intravenous Anti‐Rhesus‐D immunoglobulin (Anti‐D) is a first‐line treatment option for immune thrombocytopenia in non‐splenectomised and RhD‐positive patients. In this report, we retrospectively review our experience with intramuscular (IM) Anti‐D treatment in 74 adult patients between 1990 and 2018. We found that 73% of patients showed a response; almost all of them had complete responses (68.9%), and 26% achieved complete responses sustained at least 6 months after treatment discontinuation. [Correction added on 02 December 2022, after first online publication: In the preceding sentence, ‘(68.89%)’ has been corrected to ‘(68.9%)’ in this version.] No significant side effects were observed with no cases of acute haemolysis or anaemia reported. We conclude from this study that IM Anti‐D is an effective and safe treatment for immune thrombocytopenia.